3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
5
Gastro-enteropancreatic neuroendocrine tumor
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
7
Biopsy
6
X-Rays
5
Phantoms, Imaging
5
Temozolomide
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Carboplatin
4
selpercatinib
3
larotrectinib
3
Topotecan
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Automobiles
3
tazemetostat
2
pembrolizumab
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Vincristine
2
Surveys and Questionnaires
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Positron-Emission Tomography
2
Paclitaxel
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled